Disease · MONDO_0100491
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 19 of 19
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02672852 | BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment | Phase 3 | 507 | 2019-05-28 | Psoriasis | RISANKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03782792 | Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis | Phase 2 | 53 | 2022-03-09 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05352893 | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | Phase 3 | 45 | 2026-03-17 | Generalized Pustular Psoriasis | IMSIDOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05239039 | An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options | Phase 3 | 39 | 2024-10-09 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01794117 | Anakinra for Inflammatory Pustular Skin Diseases | Phase 2 | 18 | 2021-04-30 | Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis | ANAKINRA | Its record names the disease | ClinicalTrials.gov |
| NCT03022045 | A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Phase 3 | 18 | 2019-02-06 | Psoriasis | RISANKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01952015 | Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | Phase 3 | 12 | 2019-03-15 | Psoriasis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05200247 | An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options | Phase 3 | 11 | 2024-08-15 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02533375 | Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | Phase 3 | 10 | 2019-01-14 | Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese | ADALIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03619902 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis | Phase 2 | 8 | 2022-03-29 | Generalized Pustular Psoriasis | IMSIDOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02978690 | Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis | Phase 1 | 7 | 2023-08-21 | Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06952465 | A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis | 2,000 | Psoriasis | DEUCRAVACITINIB | Its record names the disease | ClinicalTrials.gov | ||
| NCT03886246 | Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study | Phase 2 | 131 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06391996 | Biologic Therapy for Generalized Pustular Psoriasis | 65 | Generalized Pustular Psoriasis | SECUKINUMAB, USTEKINUMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT05670821 | PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms | 52 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT05366855 | Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | Phase 3 | 42 | Generalized Pustular Psoriasis | IMSIDOLIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02343744 | An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Phase 3 | 21 | Pustular Psoriasis | GUSELKUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06323356 | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Phase 3 | 18 | Generalized Pustular Psoriasis, Erythrodermic Psoriasis | ZASOCITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT06886009 | Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis | 0 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100491/trials